TORONTO, ON / ACCESS Newswire / December 3, 2025 / Biomind Labs Inc. (" Biomind " or the " Company ") (CBOE:BMND) (OTC PINK:BMNDF) (FRA:3XI), a clinical-stage biopharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs, today announced a major strategic advancement in the development of BMND08, transitioning the program into FDA-directed activities... Read More

TORONTO, ON / ACCESS Newswire / November 25, 2025 / Biomind Labs Inc. (the " Company ") (CBOE:BMND) (OTC PINK:BMNDF) (FRA:3XI), announces that the Ontario Securities Commission (the " Commission ") has revoked its cease trade order issued on April 4, 2025 (the " FFCTO ") against the Company effective November 25, 2025. The Company was cease traded by the Commission for failure to file audited financial statements for the... Read More

TORONTO, ON / ACCESS Newswire / November 18, 2025 / Biomind Labs Inc. (the " Company ") (CBOE:BMND) (OTC PINK:BMNDF) (FRA:3XI), announces that it has filed the following continuous disclosure documents under its profile on SEDAR+ ( www.sedarplus.ca ): Amended & restated management's discussion & analysis and officers' certificates for the year ended December 31, 2024; Amended & restated management's discussion & analysis and... Read More

TORONTO, ON / ACCESSWIRE / November 20, 2024 / Biomind Labs Inc. (" Biomind " or the " Company ") (CBOE:BMND) (OTC PINK:BMNDF) (FRA:3XI) , a leading biotech company at the forefront of next-generation pharmaceuticals addressing the root causes of neurological disorders, is encouraged by the U.S. government's progressive stance on the psychedelic industry. The administration's decision to nominate a new Health Secretary with... Read More

TORONTO, ON / ACCESSWIRE / July 18, 2024 / Biomind Labs Inc. (" Biomind " or the " Company ") (CBOE:BMND) (OTC PINK:BMNDF) (FRA:3XI), a leading biotech company dedicated to developing the next-generation of pharmaceuticals targeting the root causes of neurological disorders, announced the decision to advance a new Phase II clinical trial. This decision follows new and unexpected findings from a pre-clinical study of its... Read More

TORONTO / Feb 29, 2024 / Business Wire / Biomind Labs Inc. (“ Biomind ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, today announced the successful conclusion of the Phase 2 clinical trial of its proprietary... Read More

TORONTO / Sep 27, 2023 / Business Wire / Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, provides a corporate update outlining its research and development, intellectual property and clinical trials... Read More

TORONTO / Sep 14, 2023 / Business Wire / Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce the successful completion of the first 5-Metoxi-N,N-dimethyltryptamine (“ 5-MeO-DMT ”)... Read More

TORONTO / Jun 30, 2023 / Business Wire / Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, today announced the results of matters voted on at its annual and special meeting of holders of common shares (“... Read More

TORONTO / Apr 25, 2023 / Business Wire / Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce that it has commenced a Phase II clinical trial for its proprietary... Read More

TORONTO / Mar 31, 2023 / Business Wire / Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce that it has successfully completed the optimization of a new extraction method to increase... Read More

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce that it has successfully completed the development of a novel sublingual... Read More